- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT03883594
Technology-Assisted Stepped Care Study (TASC Phase 3)
9. mars 2022 oppdatert av: Children's Hospital Medical Center, Cincinnati
Technology Assisted Stepped Care (TASC): Phase 3
The overall goal of this project is to demonstrate the feasibility, implementation, and preliminary efficacy of a technology-assisted stepped care (TASC) adherence-promotion intervention in adolescents with asthma.
This is the third phase (Phase 3) of a three-phase project to test the preliminary efficacy of a technology-assisted stepped care (TASC) intervention.
In Phase 1, we developed the intervention using patient and provider feedback from focus groups.
In Phase 2 we refined the developed intervention by having five adolescents from the focus groups test the intervention for feasibility.
In this third phase, we will enroll up to 50 adolescents to pilot-test the refined intervention for preliminary efficacy.
Studieoversikt
Status
Fullført
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Up to fifty adolescents with asthma will be enrolled in an open label pilot trial of the TASC adherence-promotion intervention for a duration of twelve months.
First, participants will complete baseline questionnaires related to demographic, and clinical predictors of adherence and asthma and a 4 week run-in phase to assess baseline adherence using electronic inhaler monitoring with a cellphone that is provided to them.
Following the run-in period, all participants will receive Step 1 of the TASC intervention for a minimum of 4 weeks.
Step 1 (Information) will include electronic educational information related to asthma symptoms and triggers, attacks, self-monitoring, treatments, action plans, and automated text message medication reminders.
Following the initial four weeks of Step 1, adherence will be evaluated and a rate of less than 68% will serve as the cause for "stepping up" to the next level of the intervention.
Adherence checks will continue to occur every four weeks for the duration of the study and adherence <68% will prompt movement from one level of treatment to the next.
Participants may remain at a treatment level for more than four weeks and may complete 1, 2, or 3 interventions steps during the 5 month study depending on the adolescent's adherence.
Step 2 (Motivation) will include electronic monitoring of adherence and personally tailored feedback via text messages.
Adolescents will be given access to the adherence tracking cellphone app and graphs of their inhaler adherence.
Adolescents will also receive brief, personalized text messages that provide supportive motivation and directive, tangible actions.
Step 3 (Behavioral) will include problem-solving telehealth intervention with a trained clinician.
Four telehealth sessions individually tailored to the unique needs and barriers of the adolescent will be provided.
The primary outcome measure will be electronically-monitored adherence assessed at post-treatment.
Secondary outcomes include asthma severity as well as process evaluation questions and quantitative measures of feasibility, acceptability, and satisfaction to demonstrate implementation.
Participants will remain in the study for an additional 7 months after they complete month 5 of the study.
For the remaining 7 months, participants will be randomized to one of two booster session patterns with the goal to improve inhaler adherence.
The statistician will make the randomization schedule and the principle investigator will maintain the randomization schedule.
Two different booster patterns are being used to test which pattern will be most effective.
The first booster session pattern will include booster sessions at the end of month 6, 8, and 12.
The second booster session pattern will include booster sessions at the end of month 6, 7, 8, 10, and 12. Booster sessions will review content provided during the intervention and the intervention delivery method will be consistent with the participants final intervention step.
Participants will also continue to complete monthly check-ins with the study coordinator to complete the Composite Asthma Severity Index, the Asthma Control Test, and a spirometry test.
Studietype
Intervensjonell
Registrering (Faktiske)
40
Fase
- Ikke aktuelt
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
Ohio
-
Cincinnati, Ohio, Forente stater, 45229
- Cincinnati Children's Medical Hospital
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
12 år til 18 år (Barn, Voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Beskrivelse
Inclusion Criteria:
- Patient age between 12-18 years
- Patient is diagnosed with severe-persistent or moderate-persistent asthma per NAEPP asthma guidelines
- Patient is prescribed at least one daily inhaled controller medication or a daily combination inhaled corticosteroid and long-acting beta-agonist and a beta-agonist bronchodilator
- English fluency for patient, caregiver, and clinician
Exclusion Criteria:
- Significant cognitive deficits that may interfere with comprehension per medical team or chart review.
- Diagnosis of serious mental illness (e.g., schizophrenia)
- Diagnosis of pervasive developmental disorder
- Active chronic disease apart from asthma or allergic disease (e.g. Bronchiectasis)
- Patient receives school administered daily controller medication at the time of the enrollment visit
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Helsetjenesteforskning
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: TASC-intervensjon
Alle deltakere mottar trinn 1 av intervensjonen.
Deltakere som har etterlevelse under eller ved 68 % vil gå opp til trinn 2 eller trinn 3 etter den tredje eller fjerde måneden i studien.
|
Trinn 1 av intervensjonen inkluderer undervisningsmateriell relatert til astma.
Trinn 2 inkluderer elektronisk overvåking av etterlevelse og en tekstmeldingsintervensjon personlig tilpasset deltakeren.
Trinn 3 inkluderer problemløsning telehelse-økter med en utdannet kliniker.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Electronic Monitoring
Tidsramme: 12 months
|
The Propeller Health monitoring system includes a Bluetooth enabled sensor that attaches to the patient's inhaler.
This sensor records every dose, or "puff", the patient takes and sends it to a corresponding online database that is accessible to study staff.
Participants will be given this sensor at baseline.
|
12 months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Spørreskjema for gjennomførbarhet/akseptabilitet
Tidsramme: 5 måneder
|
Et mål på 5-31 elementer for format, innhold, lengde, ferdigheter og aksept av intervensjonen vil bli gitt til deltakerne i form av et spørreskjema på slutten av hvert trinn og slutten av studien.
Gjennomførbarhetsdelen er på en skala fra 0 til 4, 0 er dårligst og 4 er best.
Akseptabilitetsspørreskjemaet er på en skala fra 'Ikke i det hele tatt' til 'Veldig', 'Ikke i det hele tatt' er dårligst og 'Veldig' er best.
|
5 måneder
|
Systembrukbarhetsskala
Tidsramme: 5 måneder
|
Et 10-element, Likert-skala som gir et globalt syn på brukervennlighet, vil bli gitt til deltakerne i form av et spørreskjema på slutten av hvert trinn og på slutten av studien.
Skalaen spenner fra 'Svært uenig' til 'helt enig', med halvparten av punktene omvendt.
|
5 måneder
|
Lung Function Assessment
Tidsramme: Baseline assessment and then once a month for 12 months
|
The mobile spirometer records multiple parameters of the patient's lung function including forced expiratory volume, peak expiratory flow, forced vital capacity, and forced expiratory flow.
The spirometer sends the values to the corresponding mobile phone application, Propeller Health, which is directly accessible to the patient.
|
Baseline assessment and then once a month for 12 months
|
Composite Asthma Severity Index (CASI)
Tidsramme: Baseline assessment and then once a month for 12 months
|
The participants' composite asthma severity index score will be calculated through the TreatSmart program.
TreatSmart will be used to determine the participant's symptom burden, health care utilization, systemic corticosteroid use, and current medication use to determine the level of asthma severity/control the participant has.
The program also makes an initial treatment recommendation based on the National Asthma Education and Prevention Program (NAEPP asthma guidelines).
Individuals are placed in Step 1 through Step 6 depending on the strength and frequency of their inhaled corticosteroid (1 being low dose and 6 being a high dose).
In addition, individuals are categorized as very poorly controlled, not well controlled, or well controlled based on how frequently they have had asthma symptoms or used their rescue inhaler, gone to the hospital or urgent care, or received steroids for asthma symptoms.
|
Baseline assessment and then once a month for 12 months
|
Asthma Control Test (ACT)
Tidsramme: Baseline assessment and then once a month for 12 months
|
The ACT will be used as a measure of disease severity in this study.
The ACT is a 5-question scoring tool designed for patients with asthma who are 12 years and older.
The questions ask the patient to rate their asthma severity, symptom frequency, control, and inhaler use on a scale of 1-5.
The total score is calculated by the sum of each response, which determines how well-controlled the patient's asthma is on a scale from 5-25.
|
Baseline assessment and then once a month for 12 months
|
Attendance/Participation rates
Tidsramme: 12 months
|
Participation rates will be measured 3 different ways.
The first measure will be how often participants accessed the electronic material (educational materials and/or Propeller Health app), the second measure will be how many responses to directive text messaging were received, and the third measure will be attendance to the telehealth sessions.
|
12 months
|
Acceptability of Intervention Measure (AIM)
Tidsramme: At 5 months
|
A 4 item measure of participants' belief that the intervention is acceptable will be given at the end of the study.
Participants respond to each statement on a 5 point Likert scale (1= Completely Disagree, 5= Completely Agree).
|
At 5 months
|
Intervention Appropriateness Measure (IAM)
Tidsramme: At 5 months
|
A 4 item measure of participants' perception that the intervention is appropriate will be given at the end of the study.
Participants respond to each statement on a 5 point Likert scale (1= Completely Disagree, 5= Completely Agree).
|
At 5 months
|
Feasibility of Intervention Measure (FIM)
Tidsramme: At 5 months
|
A 4 item measure of participants' belief that the intervention is feasible will be given at the end of the study.
Participants respond to each statement on a 5 point Likert scale (1= Completely Disagree, 5= Completely Agree).
|
At 5 months
|
Treatment Fidelity
Tidsramme: 12 months
|
Treatment fidelity needed for the intervention will be assessed.
Treatment fidelity will be assessed through fidelity checklists created specifically for each intervention session.
|
12 months
|
Time Needed for Intervention
Tidsramme: 12 months
|
Sessions will be timed and the number of weeks to complete the session will be tracked to determine the average length of time needed for the intervention.
|
12 months
|
Perceived Characteristics of Intervention Scale
Tidsramme: At 12 months
|
19 item measure of interventionist views toward the study intervention.
|
At 12 months
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Behavior Assessment System for Children-Third Edition, Self-report of Personality (BASC-3-SRP-A
Tidsramme: Baseline assessment and at 5 months
|
The BASC-3 is a widely used, reliable (α= 0.94 - 0.96 , test-retest r= 0.81 -0.82), and valid inventory to assess emotional and behavioral symptoms in adolescents and young adults (ages 13-21).
|
Baseline assessment and at 5 months
|
Adolescent Barriers to Medication Scales (AMBS)
Tidsramme: Baseline Assessment
|
The AMBS is an 18-item validated measure of perceived barriers to medication adherence in adolescents.
|
Baseline Assessment
|
Technology-based Experience of Need Satisfaction- Interface questionnaire (TENS-Interface)
Tidsramme: Baseline assessment and then at 2 months
|
A 15- item measure of participant's competence, autonomy, and relatedness in using technology.
Participants rate their level of agreement to each statement on a 5- point Likert scale (1= Do Not Agree, 5= Strongly Agree).
|
Baseline assessment and then at 2 months
|
Autonomy and Competence in Technology Adoption Questionnaire (ACTA)
Tidsramme: Baseline Assessment
|
A 10-item measure of why people adopt use of a technology (i.e.
download an app, register with a website, purchase a wearable device, etc.).Participants respond to self-regulation statements on a scale of 1 to 5, 1 being 'not at all true' and 5 being 'very true.'
|
Baseline Assessment
|
Technology-based Experience of Need Satisfaction- Task questionnaire (TENS- Task)
Tidsramme: Baseline assessment and then at 2 months
|
An 8-item measure of participant's competence, autonomy, and relatedness in managing their asthma using technology.
Participants rate their level of agreement to each statement on a 5- point Likert scale (1= Do Not Agree, 5= Strongly Agree).
|
Baseline assessment and then at 2 months
|
Technology Effects on Need Satisfaction in Life (TENS- Life)
Tidsramme: Baseline assessment and then at 2 months
|
The TENS-Life is a 10- item measure of the extent to which a user perceives that the use of a particular technology has had an influence on the satisfaction of basic psychological needs in their life.
Participants rate their level of agreement to each statement on a 5- point Likert scale (1= Do Not Agree, 5= Strongly Agree).
|
Baseline assessment and then at 2 months
|
Kunnskapsspørreskjema
Tidsramme: Grunnlinjevurdering
|
Et 13-elements spørreskjema som vurderer individets kunnskap om astmasymptomer, triggere og medisiner.
Deltakerne vurderer sitt nivå av enighet til hvert utsagn på en skala fra 'helt enig' til 'helt uenig'.
Dette spørreskjemaet vil bli fylt ut ved baseline-besøket.
|
Grunnlinjevurdering
|
Hardship spørreskjema
Tidsramme: Grunnlinjevurdering
|
Et 19-elements validert spørreskjema som vurderer den økonomiske belastningen til enkeltpersoner i en husholdning.
|
Grunnlinjevurdering
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
7. desember 2018
Primær fullføring (Faktiske)
20. april 2021
Studiet fullført (Faktiske)
20. april 2021
Datoer for studieregistrering
Først innsendt
8. februar 2019
Først innsendt som oppfylte QC-kriteriene
19. mars 2019
Først lagt ut (Faktiske)
21. mars 2019
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
10. mars 2022
Siste oppdatering sendt inn som oppfylte QC-kriteriene
9. mars 2022
Sist bekreftet
1. mars 2022
Mer informasjon
Begreper knyttet til denne studien
Andre studie-ID-numre
- CIN001- {"TASC Phase 3"}
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
UBESLUTTE
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .